Product Description
Mechanisms of Action: HSPE Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: Orphan Drug - Trypanosomiasis, African *
Approval Status: Not Approved
Approved Countries: Germany | India | Pakistan | South Africa
Approved Indications: None
Known Adverse Events: None
Company: Optimum
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Acute Kidney Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RLS003-02-001 | P2 |
Active, not recruiting |
Acute Kidney Injury |
2023-04-17 |
24% |